Gabrielle Jongeneel1, Marjolein J E Greuter2, Felice N van Erning3, Miriam Koopman4, Geraldine R Vink3, Cornelis J A Punt5, Veerle M H Coupé2. 1. Department of Epidemiology and Data Science, Amsterdam UMC, VU University, PO Box 7057, MF F-wing, Amsterdam, 1007 MB, the Netherlands. 2. Department of Epidemiology and Data Science, Amsterdam UMC, VU University, Amsterdam, The Netherlands. 3. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 4. Department of medical oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 5. Department of Epidemiology, University Medical Center Utrecht, Julius Center for Health Sciences, Utrecht, The Netherlands.
Abstract
BACKGROUND: We aimed to evaluate the cost-effectiveness of risk-based strategies to improve the selection of surgically treated stage II colon cancer (CC) patients for adjuvant chemotherapy. METHODS: Using the 'Personalized Adjuvant TreaTment in EaRly stage coloN cancer' (PATTERN) model, we evaluated five selection strategies: (1) no chemotherapy, (2) Dutch guideline recommendations assuming observed adherence, (3) Dutch guideline recommendations assuming perfect adherence, (4) biomarker mutation OR pT4 stage strategy in which patients with MSS status combined with a pT4 stage or a mutation in BRAF and/or KRAS receive chemotherapy assuming perfect adherence and (5) biomarker mutation AND pT4 stage strategy in which patients with MSS status combined with a pT4 stage tumor and a BRAF and/or KRAS mutation receive chemotherapy assuming perfect adherence. Outcomes were number of CC deaths per 1000 patients and total discounted costs and quality-adjusted life-years (QALYs) per patient (pp). Analyses were conducted from a societal perspective. The robustness of model predictions was assessed in sensitivity analyses. RESULTS: The reference strategy, that is, no adjuvant chemotherapy, resulted in 139 CC deaths in a cohort of 1000 patients, 8.077 QALYs pp and total costs of €22,032 pp. Strategies 2-5 were more effective (range 8.094-8.217 QALYs pp and range 118-136 CC deaths per 1000 patients) and more costly (range €22,404-€25,102 pp). Given a threshold of €50,000/QALY, the optimal use of resources would be to treat patients with either the full adherence strategy and biomarker mutation OR pT4 stage strategy. CONCLUSION: Selection of stage II CC patients for chemotherapy can be improved by either including biomarker status in the selection strategy or by improving adherence to the Dutch guideline recommendations.
BACKGROUND: We aimed to evaluate the cost-effectiveness of risk-based strategies to improve the selection of surgically treated stage II colon cancer (CC) patients for adjuvant chemotherapy. METHODS: Using the 'Personalized Adjuvant TreaTment in EaRly stage coloN cancer' (PATTERN) model, we evaluated five selection strategies: (1) no chemotherapy, (2) Dutch guideline recommendations assuming observed adherence, (3) Dutch guideline recommendations assuming perfect adherence, (4) biomarker mutation OR pT4 stage strategy in which patients with MSS status combined with a pT4 stage or a mutation in BRAF and/or KRAS receive chemotherapy assuming perfect adherence and (5) biomarker mutation AND pT4 stage strategy in which patients with MSS status combined with a pT4 stage tumor and a BRAF and/or KRAS mutation receive chemotherapy assuming perfect adherence. Outcomes were number of CC deaths per 1000 patients and total discounted costs and quality-adjusted life-years (QALYs) per patient (pp). Analyses were conducted from a societal perspective. The robustness of model predictions was assessed in sensitivity analyses. RESULTS: The reference strategy, that is, no adjuvant chemotherapy, resulted in 139 CC deaths in a cohort of 1000 patients, 8.077 QALYs pp and total costs of €22,032 pp. Strategies 2-5 were more effective (range 8.094-8.217 QALYs pp and range 118-136 CC deaths per 1000 patients) and more costly (range €22,404-€25,102 pp). Given a threshold of €50,000/QALY, the optimal use of resources would be to treat patients with either the full adherence strategy and biomarker mutation OR pT4 stage strategy. CONCLUSION: Selection of stage II CC patients for chemotherapy can be improved by either including biomarker status in the selection strategy or by improving adherence to the Dutch guideline recommendations.
Authors: L Tilson; L Sharp; C Usher; C Walsh; Whyte S; A O'Ceilleachair; C Stuart; B Mehigan; M John Kennedy; P Tappenden; J Chilcott; A Staines; H Comber; M Barry Journal: Eur J Health Econ Date: 2011-06-03
Authors: Matthijs M Versteegh; Karin M Vermeulen; Silvia M A A Evers; G Ardine de Wit; Rilana Prenger; Elly A Stolk Journal: Value Health Date: 2016-03-30 Impact factor: 5.725
Authors: Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Mandy Van Den Brink; Wilbert B Van Den Hout; Anne M Stiggelbout; Elma Klein Kranenbarg; Corrie A M Marijnen; Cornelis J H Van De Velde; Job Kievit Journal: J Clin Oncol Date: 2003-12-09 Impact factor: 44.544
Authors: Gabrielle Jongeneel; Thomas Klausch; Felice N van Erning; Geraldine R Vink; Miriam Koopman; Cornelis J A Punt; Marjolein J E Greuter; Veerle M H Coupé Journal: Int J Cancer Date: 2019-08-31 Impact factor: 7.316
Authors: Gabrielle Jongeneel; Marjolein J E Greuter; Natalia Kunst; Felice N van Erning; Miriam Koopman; Jan P Medema; Louis Vermeulen; Jan N M Ijzermans; Geraldine R Vink; Cornelis J A Punt; Veerle M H Coupé Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-06-23 Impact factor: 4.090